Asep Medical’s Sepsis Diagnostic Technology Can Provide Improved Odds for Pediatric Appendicitis
VANCOUVER, BC, Feb. 27, 2024 /PRNewswire/ – Asep Medical Holdings Inc. (“Asep Inc.” or the “Company“) (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) is pleased to announce that its proprietary gene expression signature for sepsis can provide an improved assessment of the severity of appendicitis in children. According to Dr. Rob Stenstrom, Asep’s Medical Director, “Abdominal pain is one of the most common complaints we see for children in the emergency room, and so it’s important that we identify the difference between simple appendicitis and perforated appendicitis quickly and accurately.”
Related news for (SEPSF)
- Asep Medical Featured in National Documentary
- Asep Medical Holdings Inc. to Hold Significant Investor Information Webinar this Friday, March 22, 2024, at 4 pm EST
- Asep Medical Confirms the Use of AI – Enables Improved Treatments for Common Biofilm Infections and Rapid Sepsis Diagnostics
- ASEP INC. ANNOUNCES CLOSING OF DEBT SETTLEMENT